Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients With Thin Cutaneous Melanoma Tumors


FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a study that establishes an evidence-based population to guide appropriate use of the DecisionDx®-Melanoma test in patients with thinner tumors. The study was published in the peer-reviewed journal SKIN: The Journal of Cutaneous Medicine. Current best practice for the use of DecisionD…

- Advertisement -